AUS
NZ
UK
CA
USA
IND
Allied Minds Plc
Allied Minds plc (LON:ALM) is the United States domiciled IP commercialisation company focused on early-stage company development within the technology sector with origination relationships that span across United States federal laboratories, universities, and leading United States corporations, Allied Minds historically conceptualised as an intellectual property commercialisation company, now operates and funds, a portfolio of companies to generate long-term value for its investors and stakeholders. The company is based in Boston in the United States of America and supports its portfolio of businesses with capital, management, expertise and shared services.
The shares of the company have their listing on the main market segment of the London Stock Exchange, where its shares trade with the ticker name ALM. The shares of the company form part of the FTSE All- Share index.
Trading Update
The company on 11 December 2019 came out with news Update on the recent Board Changes and restructuring activities undertaken by the company.
- The current CEO Mike Turner will be stepping down from his position on 10 March 2020.
- The company will be able to reduce its HQ expenses to $6.00 million instead of the previously guided $7.50 million.
Stock Performance at the London Stock Exchange
Source â Thomson Reuters
At the time of writing of this report (12.19 PM GMT) on 24 December 2019 the shares of the company were trading on the London Stock Exchange for GBX 50.2.
The shares of the company during the past 52 weeks of trading at the London Stock Exchange have registered a 52-week high of GBX 88.86 while also registering a 52-week low of GBX 43.02. The company has a market capitalisation of £119.63 million on the London Stock Exchange at the time of writing this report on 24 December 2019.
The stockâs average traded volume as on the above date and time stood at 386,817, and the stock's average traded volume for 5 days was 1,216,729.00; 30 days- 853,116.00 and 90 days â 1,260,823.67 and the beta of the stock of the company on the date was 1.63, which compared to the benchmark index reflected a lower volatility. The stocks trading volumes on the London Stock Exchange on an average for 5 days was up by +42.62 % as compared to the 30 daysâ average traded volume, and in last one month, the shares have generated a return of -0.40 % and also a return of -29.77 % on year to date basis.
Outlook
The company is in the process of a restructuring exercise which is meant to streamline its activities and the savings entailed at the company HQ and the disposal of the Hawkeye asset in this regard.
Kier Group Plc
Kier Group plc (LON:KIE) is the United Kingdom domiciled construction and property development company specialised in residential and commercial property development and infrastructure project investment. The company, through its services caters to various sectors including utilities, power, housing, defence, institutional, commercial, education and industrial sectors. Woodford Investment Management Ltd, Aberdeen Standard Investments and BlackRock Advisors (UK) Ltd are the top institutional investors in the company.
 The shares of the company have their listing on the main market segment of the London Stock Exchange, where its shares trade with the ticker name KEI. The shares of the company form part of the FTSE All-Share index.
Trading Update
On 16 December 2019 the company came out with an update on the appointment of the new Chairman of the company.
- Matthew Lester has been appointed as the new Chairman of the Board of Directors of the company effective from 1 January 2020.
- Matthew will be replacing Philip Cox, who will remit office on the same day.
Stock Performance at the London Stock Exchange
Source â Thomson Reuters
At the time of writing of this report on 24 December 2019 at 12.27 PM GMT, the shares of the company were trading on the London Stock Exchange for GBX 97.14.
The shares of the company during the past 52 weeks of trading at the London Stock Exchange have registered a 52-week high of GBX 547.00, while also registering a 52-week low of GBX 58.40. The company has a market capitalisation of £152.23 million on the London Stock Exchange at the time of writing this report on 24 December 2019.
The stockâs average traded volume as on the above date and time stood at 508,167, and the stock's average traded volume for 5 days was 873,648.60; 30 days- 1,140,357.77 and 90 days â 1,354,901.76 and the beta of the stock of the company on the date was -0.32, which compared to the benchmark index reflected a volatility in the inverse direction. The stocksâ trading volumes on the London Stock Exchange on an average for 5 days was up by  -23.39 % as compared to the 30 daysâ average traded volume, and in last one month, the shares have generated a return of +4.36 % and also a return of -77.11 % on year to date basis.
CMC Markets Plc
CMC Markets Plc (LON:CMCX) is the United Kingdom domiciled financial instruments dealing company primarily into derivative instruments. The company is now one of the world's leading online financial trading businesses it also serves retail and institutional clients through regulated offices and branches in 13 countries, with a significant presence in the UK, Australia, Germany and Singapore. Established in 1989 the company offers an award-winning, online and mobile trading platform, enabling clients to trade up to 10,000 financial instruments across shares, indices, foreign currencies, commodities and treasuries through contracts for difference (CFDs), financial spread bets (in the UK and Ireland only) and, in Australia, access stockbroking services.
The shares of the company have their listing on the main market segment of the London Stock Exchange, where its shares trade with the ticker name CMCX. The shares of the company form part of the FTSE All- Share index.
Trading Update
The company on 21 November 2019 came out with its interim six-month results for the period ending on 30 September 2019.
- The Net operating income of the company for the period stood at £3 million over a corresponding previous period Net operating income of £70.6 million, a growth of 45 per cent.
- The Profit before tax of the company for the period stood at £1 million over a corresponding previous period Profit before tax of £7.2 million, registering a growth of 318 per cent.
Stock Performance at the London Stock Exchange
Source â Thomson Reuters
At the time of writing of this report on 24 December 2019, at 12.26 PM, the shares of the company were trading on the London Stock Exchange for GBX 146.8.
The shares of the company during the past 52 weeks of trading at the London Stock Exchange have registered a 52-week high of GBX 153.40, while also registering a 52-week low of GBX 74.30. The company has a market capitalisation of £432.51 million on the London Stock Exchange at the time of writing this report on 24 December 2019.
The stockâs average traded volume as on the above date and time stood at 112,086, and the stock's average traded volume for 5 days was 277,610.20; 30 days- 250,782.70 and 90 days â 228,214.07 and the beta of the stock of the company on the date was -0.32, which compared to the benchmark index reflected a volatility in the inverse direction. The stocks trading volumes on the London Stock Exchange on an average for 5 days was up by +10.70 % as compared to the 30 daysâ average traded volume, and in last one month, the shares have generated a return of +14.46 % and also a return of +41.44 % return on year to date basis.
PureTech Health Plc
PureTech Health Plc (LON:PRTC), is the United States domiciled advanced biopharmaceutical company which is engaged in discovering, developing and commercialising new categories of therapeutics based on the science of the Brain-Immune-Gut (BIG) axis for potentially difficult to treat diseases including intractable cancers, immunological diseases, inflammatory, CNS disorders, lymphatic and GI diseases. The group collaborates with major pharma companies across the world through its affiliate and internal R&D pipelines, and its portfolio includes one FDA cleared product, 24 product candidates and another 14 in clinical-stage products. The operations of the group are differentiated in four operating segments, namely Internal, Subsidiaries, Deconsolidated Entities and Parent Company & other.
The shares of the company have their listing on the main market segment of the London Stock Exchange, where its shares trade with the ticker name PRTC. The shares of the company form part of the FTSE 250 index.
Trading Update
The company on 9 December 2019 came out with a trading update on the new capital funding its affiliate Gelesis has been able to garner for the commercialisation of its anti-obesity drug PLENITYâ¢.
- The latest round of funding has been led by Vitruvian Partners who have provided $63.4 million in equity plus more funding has also been garnered via grants and loans.
Stock Performance at the London Stock Exchange
Source â Thomson Reuters
At the time of writing of this report on 24 December 2019 at 12:35 PM GMT, the shares of the company were trading on the London Stock Exchange for GBX 302.00.
The shares of the company during the past 52 weeks of trading at the London Stock Exchange have registered a 52-week high of GBX 307.00, while also registering a 52-week low of GBX 155.50. The company has a market capitalisation of £860.60 million on the London Stock Exchange at the time of writing this report on 24 December 2019.
The stockâs average traded volume as on the above date and time stood at 46,296, and the stock's average traded volume for 5 days was 175,515.40; 30 days- 241,521.63 and 90 days â 157,397.56 and the beta of the stock of the company on the date was 0.86, which compared to the benchmark index reflected a lower volatility. The stocks trading volumes on the London Stock Exchange on an average for 5 days was up by -27.33% as compared to the 30 daysâ average traded volume, and in last one month, the shares have generated a return of +6.01% and also a return of +74.42% return on year to date basis.
